9. Questcor Pharmaceuticals ( QCOR) has surged 220% in 2010. The Union City, Calif.-based company has grown 12-month sales 25%. Its drug Acthar, used to treat multiple sclerosis, saw a 129% jump in quarterly paid prescriptions.

12-Month Sales Growth: 25%
12-Month Net Income Growth: 7.6%
Cash Flow Multiple: 19 (68% peer premium)
Quarterly Operating Profit Margin: 54%

Analyst Opinions: Just three researchers follow Questcor, with two rating its stock "buy" and one ranking it "hold." Oppenheimer forecasts that the stock will advance 24% to $19. The shares certainly have technical momentum. They've appreciated 44% in the past three months. Acthar was recently approved by the FDA as a safe treatment for infantile spasms, expanding the drug's revenue potential. It is now approved to treat more than 29 disorders.

If you liked this article you might like

Analysts' Actions -- Autodesk, Estee Lauder, Newell Brands, Western Digital and More

Analysts' Actions -- Seagate, Time Warner, Travelzoo, United Technologies and More

Buy Oversold Travelzoo Now for a 33% Bounce Back to Fair Value

5 Hated Earnings Stocks You Should Love

Insider Trading Alert - ROVI, ODC And TZOO Traded By Insiders